KR102660196B1 - 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용 - Google Patents

치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용 Download PDF

Info

Publication number
KR102660196B1
KR102660196B1 KR1020197023280A KR20197023280A KR102660196B1 KR 102660196 B1 KR102660196 B1 KR 102660196B1 KR 1020197023280 A KR1020197023280 A KR 1020197023280A KR 20197023280 A KR20197023280 A KR 20197023280A KR 102660196 B1 KR102660196 B1 KR 102660196B1
Authority
KR
South Korea
Prior art keywords
triazolo
dimethyl
piperidin
phenyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197023280A
Other languages
English (en)
Korean (ko)
Other versions
KR20190098266A (ko
Inventor
수이시옹 차이
예 에드워드 티안
Original Assignee
임팩트 테라퓨틱스 (상하이), 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임팩트 테라퓨틱스 (상하이), 인코포레이티드 filed Critical 임팩트 테라퓨틱스 (상하이), 인코포레이티드
Publication of KR20190098266A publication Critical patent/KR20190098266A/ko
Application granted granted Critical
Publication of KR102660196B1 publication Critical patent/KR102660196B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197023280A 2017-01-09 2018-01-09 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용 Active KR102660196B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710014520 2017-01-09
CN201710014520.1 2017-01-09
PCT/CN2018/071851 WO2018127195A1 (zh) 2017-01-09 2018-01-09 取代的稠合杂芳基化合物作为激酶抑制剂及其应用

Publications (2)

Publication Number Publication Date
KR20190098266A KR20190098266A (ko) 2019-08-21
KR102660196B1 true KR102660196B1 (ko) 2024-04-24

Family

ID=62789082

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197023280A Active KR102660196B1 (ko) 2017-01-09 2018-01-09 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용

Country Status (8)

Country Link
US (1) US10874670B2 (https=)
EP (1) EP3567041B1 (https=)
JP (1) JP7247092B2 (https=)
KR (1) KR102660196B1 (https=)
CN (1) CN110167941B (https=)
AU (1) AU2018206111B2 (https=)
CA (1) CA3049608A1 (https=)
WO (1) WO2018127195A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981918B2 (en) 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives
DK3823971T3 (da) 2018-07-20 2022-09-05 Gruenenthal Gmbh Substituerede triazol-quinoxalin-derivater
US20220259211A1 (en) * 2019-07-10 2022-08-18 Impact Therapeutics (Shanghai), Inc Substituted pyrazoloquinazolinone compounds and application thereof
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US20220354859A1 (en) * 2019-09-12 2022-11-10 Impact Therapeutics (Shanghai), Inc Substituted imidazoquinoxaline compounds and uses thereof
CA3178738A1 (en) 2020-04-29 2021-11-04 Shenzhen Shokz Co., Ltd. Acoustic devices and magnetic circuit assemblies thereof
KR102458689B1 (ko) * 2020-07-08 2022-10-25 원광대학교산학협력단 피페리딘 화합물 및 이의 제조 방법
AU2022264775A1 (en) * 2021-04-26 2023-11-09 Ohio State Innovation Foundation Lipid nanomaterials and uses thereof
CN118103373A (zh) * 2023-01-18 2024-05-28 上海德琪医药科技有限公司 Prmt5抑制化合物和其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
JP2013537204A (ja) 2010-09-16 2013-09-30 ハチソン メディファーマ リミテッド 縮合ヘテロアリールおよびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
DE102010025786A1 (de) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
CN103124731B (zh) * 2010-09-16 2016-01-20 和记黄埔医药（上海）有限公司 稠合的杂芳基化合物及其应用
NO2714752T3 (https=) * 2014-05-08 2018-04-21

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
JP2013537204A (ja) 2010-09-16 2013-09-30 ハチソン メディファーマ リミテッド 縮合ヘテロアリールおよびその使用

Also Published As

Publication number Publication date
US20190358225A1 (en) 2019-11-28
US10874670B2 (en) 2020-12-29
CN110167941A (zh) 2019-08-23
CN110167941B (zh) 2023-04-04
JP7247092B2 (ja) 2023-03-28
EP3567041C0 (en) 2023-12-27
AU2018206111A1 (en) 2019-08-22
AU2018206111B2 (en) 2022-07-21
CA3049608A1 (en) 2018-07-12
JP2020504139A (ja) 2020-02-06
EP3567041A1 (en) 2019-11-13
EP3567041A4 (en) 2020-08-05
EP3567041B1 (en) 2023-12-27
WO2018127195A1 (zh) 2018-07-12
EP3567041A9 (en) 2022-04-20
KR20190098266A (ko) 2019-08-21

Similar Documents

Publication Publication Date Title
KR102660196B1 (ko) 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
WO2022199652A1 (en) Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
CN118215664B (zh) 取代的三唑并杂芳基化合物作为usp1抑制剂及其应用
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
WO2022253188A1 (en) Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
EP4028393A1 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
US11547703B2 (en) Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
EP4267581A1 (en) Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof
WO2024083237A1 (en) Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof
CN114026097B (zh) 取代的吡唑并喹唑啉酮化合物及其应用
CN116529251A (zh) 取代的稠合双环化合物作为激酶抑制剂及其应用
CN114787162B (zh) 取代的咪唑并喹喔啉化合物及其应用
EP4673448A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
CN112480120A (zh) 取代的咪唑并喹喔啉化合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000